BioSig Technologies Inc. (BSGM) stock rises during pre-market trading session. Here’s what’s happening?

0
461

BioSig Technologies Inc. (NASDAQ: BSGM) stock declined by 2.53% at the last close whereas the BSGM stock price soars by 5.52% in the pre-market trading session. BioSig Technologies is a medical technology business that sells a biomedical signal processing platform that enhances the signal quality and reveals the entire spectrum of ECG and intra-cardiac signals.

>> 7 Top Picks for the Post-Pandemic Economy << 

BSGM stock’ Recent Development

The Mark E. Josephson Twenty-Eight Annual State-of-the-Art Arrhythmia Symposium, which will take place electronically on September 11, 2021, has invited BioSig Technologies to attend.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Read More

Kenneth L. Londoner, Chairman, and CEO of BSGM stock stated,

The intellectual integrity of Dr. Josephson, as well as his steadfast commitment to the advancement of cardiac electrophysiology, was the motivating factor behind my choice to focus on basic research throughout the development of their flagship device, the PURE EP. Many of them who had the pleasure of knowing Dr. Josephson will recall his remarks that the industry needed to “move away from observation and toward invention.” These phrases sum up their company’s aim to provide more creative treatments for every arrhythmia sufferer. They are pleased to be invited to the conference that builds on his scientific and clinical legacy, four years after his death.

Moreover,

The PURE EP is a non-invasive class II device designed to improve electrophysiological procedure efficiency and efficacy. Over 60 clinicians have used the PURE EP System to finish over 1200 patient cases across eleven clinical sites. The FDA has granted the PURE EP System 510(k) approval.

Cardiac arrhythmia affects one in every 18 Americans. The most prevalent arrhythmia is atrial fibrillation, which affects over 33 million individuals globally, including over 6 million in the United States. By 2050, the number of persons with atrial fibrillation is anticipated to rise to 8-12 million. As per the Centers for Disease Control and Prevention, atrial fibrillation leads to more than 750,000 hospitalizations in the United States each year, costing $6 billion in healthcare costs.

LEAVE A REPLY

Please enter your comment!
Please enter your name here